Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results
REGENXBIO has been downgraded from 'Buy' to 'Hold' following regulatory challenges for its drug RGX-121. The company received a Complete Response Letter and faces an uncertain path for RGX-202 despite positive phase 3 results. With cash reserves only lasting until early 2027, financing concerns are growing as pivotal trial data approaches.
- ▪REGENXBIO was downgraded from 'Buy' to 'Hold' due to regulatory setbacks.
- ▪The company received a Complete Response Letter for RGX-121 and faces an uncertain appeals process.
- ▪Positive phase 3 data for RGX-202 showed strong results, but FDA approval remains uncertain.
Seeking Alpha files mainly under finance. We currently carry 6,355 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905590-regenxbio-hold-on-rgx-121-crl-mps-ii-and-rgx-202-dmd-results"},"author":{"@type":"Person","name":"Terry Chrisomalis","url":"https://seekingalpha.com/author/terry-chrisomalis"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
